Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2015
Institutional clinical trial accrual volume and survival of patients with head and neck cancer.
Abstract readClinical Trial, Phase IIIComparative StudyMulticenter Study
In one paragraph
Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 92 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
92citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
92 citing papers in PubMed, 1 synthesis or guideline pooled it.
- If health organisations and staff engage in research, does healthcare improve? Strengthening the evidence base through systematic reviews.Health research policy and systems · 2024Pooled it
- Nomogram to Predict the Benefit of Intensive Treatment for Locoregionally Advanced Head and Neck Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2019Trial
- Pentoxifylline and vitamin E reduce the severity of radiotherapy-induced oral mucositis and dysphagia in head and neck cancer patients: a randomized, controlled study.Medical oncology (Northwood, London, England) · 2019Trial
- Radiotherapy quality assurance for the RTOG 0834/EORTC 26053-22054/NCIC CTG CEC.1/CATNON intergroup trial "concurrent and adjuvant temozolomide chemotherapy in newly diagnosed non-1p/19q deleted anaplastic glioma": Individual case review analysis.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2018Trial
- Institutional Enrollment and Survival Among NSCLC Patients Receiving Chemoradiation: NRG Oncology Radiation Therapy Oncology Group (RTOG) 0617.Journal of the National Cancer Institute · 2016Trial
- Comparison of Patient- and Practitioner-Reported Toxic Effects Associated With Chemoradiotherapy for Head and Neck Cancer.JAMA otolaryngology-- head & neck surgery · 2016Trial
- Lungtech, a phase II EORTC trial of SBRT for centrally located lung tumours - a clinical physics perspective.Radiation oncology (London, England) · 2016Trial
- Multicentre patterns-of-care analysis of adjuvant and definitive (chemo)radiotherapy for pharyngeal and laryngeal carcinoma in Franconia, Germany.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2026Observational
- Institutional enrollment volume and clinical outcomes after surgery or chemoradiotherapy for clinical stage I esophageal squamous cell carcinoma: a supplementary analysis of JCOG0502.Esophagus : official journal of the Japan Esophageal Society · 2026Article
- Determining optimal transit dosimetry gamma parameter values for the detection of failure modes using receiver operating curve analysis.Journal of applied clinical medical physics · 2026Article
- A dual-layer quality assurance approach leveraging dose prediction for efficient review of automated contours of organs at risk in the brain in radiotherapy.Physics and imaging in radiation oncology · 2025Article
- Geometric and dosimetric evaluation of a commercial AI auto-contouring tool on multiple anatomical sites in CT scans.Journal of applied clinical medical physics · 2025Article
- Validating knowledge-based volumetric modulated arc therapy plans with a multi-institution model (broad model) using a complete open-loop dataset for prostate cancer.Physical and engineering sciences in medicine · 2025Article
- Choice of Adjuvant Radiotherapy Facility in Sinonasal Squamous Cell Carcinoma.The Laryngoscope · 2025Article
- Impact of Adjuvant Radiotherapy Setting on Quality-of-Life in Head and Neck Squamous Cell Carcinoma.The Laryngoscope · 2024Observational
- Increasing radiation therapy and lower survival for human papillomavirus-related oropharynx cancer associated with a shift to community cancer center care.Journal of the National Cancer Institute · 2024Article
- Uncovering the armpit of SBRT: An institutional experience with stereotactic radiation of axillary metastases.Clinical and translational radiation oncology · 2024Article
- Review
- Are there differences in revision stapes surgery outcomes between university and county clinics? A study from the quality register for otosclerosis surgery in Sweden.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2023Article
- Traditional risk factors and nodal yield-still relevant with high-quality risk-adapted adjuvant treatment for locally advanced head and neck cancer?Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2023Article
32 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
15 authors.
Evan J WuthrickEvan J. Wuthrick and Maura L. Gillison, Ohio State University Medical Center, Columbus; Mitchell Machtay, Case Western Reserve University, Cleveland, OH; Qiang Zhang, Jonathan Harris, and Qian Wu, Radiation Therapy Oncology Group Statistical Center; Eric M. Horwitz, Fox Chase Cancer Center, Philadelphia, PA; David I. Rosenthal, University of Texas MD Anderson Cancer Center, Houston, TX; Phuc Felix Nguyen-Tan, Centre Hospitalier de l'Université de Montréal-Notre Dame, Montreal; André Fortin, Hôtel-Dieu de Quebec, Quebec City, Quebec; Nancy E. Read, Western University, London Regional Cancer Center, London, Ontario, Canada; Craig L. Silverman, James Graham Brown Cancer Center, University of Louisville, Louisville, KY; Adam Raben, Christiana Care Helen F. Graham Cancer Center, Newark, DE; Harold E. Kim, Wayne State University, Detroit, MI; and Quynh-Thu Le, Stanford University, Palo Alto, CA. evan.wuthrick@osumc.edu.
Qiang ZhangEvan J. Wuthrick and Maura L. Gillison, Ohio State University Medical Center, Columbus; Mitchell Machtay, Case Western Reserve University, Cleveland, OH; Qiang Zhang, Jonathan Harris, and Qian Wu, Radiation Therapy Oncology Group Statistical Center; Eric M. Horwitz, Fox Chase Cancer Center, Philadelphia, PA; David I. Rosenthal, University of Texas MD Anderson Cancer Center, Houston, TX; Phuc Felix Nguyen-Tan, Centre Hospitalier de l'Université de Montréal-Notre Dame, Montreal; André Fortin, Hôtel-Dieu de Quebec, Quebec City, Quebec; Nancy E. Read, Western University, London Regional Cancer Center, London, Ontario, Canada; Craig L. Silverman, James Graham Brown Cancer Center, University of Louisville, Louisville, KY; Adam Raben, Christiana Care Helen F. Graham Cancer Center, Newark, DE; Harold E. Kim, Wayne State University, Detroit, MI; and Quynh-Thu Le, Stanford University, Palo Alto, CA.
Mitchell MachtayEvan J. Wuthrick and Maura L. Gillison, Ohio State University Medical Center, Columbus; Mitchell Machtay, Case Western Reserve University, Cleveland, OH; Qiang Zhang, Jonathan Harris, and Qian Wu, Radiation Therapy Oncology Group Statistical Center; Eric M. Horwitz, Fox Chase Cancer Center, Philadelphia, PA; David I. Rosenthal, University of Texas MD Anderson Cancer Center, Houston, TX; Phuc Felix Nguyen-Tan, Centre Hospitalier de l'Université de Montréal-Notre Dame, Montreal; André Fortin, Hôtel-Dieu de Quebec, Quebec City, Quebec; Nancy E. Read, Western University, London Regional Cancer Center, London, Ontario, Canada; Craig L. Silverman, James Graham Brown Cancer Center, University of Louisville, Louisville, KY; Adam Raben, Christiana Care Helen F. Graham Cancer Center, Newark, DE; Harold E. Kim, Wayne State University, Detroit, MI; and Quynh-Thu Le, Stanford University, Palo Alto, CA.
David I RosenthalEvan J. Wuthrick and Maura L. Gillison, Ohio State University Medical Center, Columbus; Mitchell Machtay, Case Western Reserve University, Cleveland, OH; Qiang Zhang, Jonathan Harris, and Qian Wu, Radiation Therapy Oncology Group Statistical Center; Eric M. Horwitz, Fox Chase Cancer Center, Philadelphia, PA; David I. Rosenthal, University of Texas MD Anderson Cancer Center, Houston, TX; Phuc Felix Nguyen-Tan, Centre Hospitalier de l'Université de Montréal-Notre Dame, Montreal; André Fortin, Hôtel-Dieu de Quebec, Quebec City, Quebec; Nancy E. Read, Western University, London Regional Cancer Center, London, Ontario, Canada; Craig L. Silverman, James Graham Brown Cancer Center, University of Louisville, Louisville, KY; Adam Raben, Christiana Care Helen F. Graham Cancer Center, Newark, DE; Harold E. Kim, Wayne State University, Detroit, MI; and Quynh-Thu Le, Stanford University, Palo Alto, CA.
Phuc Felix Nguyen-TanEvan J. Wuthrick and Maura L. Gillison, Ohio State University Medical Center, Columbus; Mitchell Machtay, Case Western Reserve University, Cleveland, OH; Qiang Zhang, Jonathan Harris, and Qian Wu, Radiation Therapy Oncology Group Statistical Center; Eric M. Horwitz, Fox Chase Cancer Center, Philadelphia, PA; David I. Rosenthal, University of Texas MD Anderson Cancer Center, Houston, TX; Phuc Felix Nguyen-Tan, Centre Hospitalier de l'Université de Montréal-Notre Dame, Montreal; André Fortin, Hôtel-Dieu de Quebec, Quebec City, Quebec; Nancy E. Read, Western University, London Regional Cancer Center, London, Ontario, Canada; Craig L. Silverman, James Graham Brown Cancer Center, University of Louisville, Louisville, KY; Adam Raben, Christiana Care Helen F. Graham Cancer Center, Newark, DE; Harold E. Kim, Wayne State University, Detroit, MI; and Quynh-Thu Le, Stanford University, Palo Alto, CA.
André FortinEvan J. Wuthrick and Maura L. Gillison, Ohio State University Medical Center, Columbus; Mitchell Machtay, Case Western Reserve University, Cleveland, OH; Qiang Zhang, Jonathan Harris, and Qian Wu, Radiation Therapy Oncology Group Statistical Center; Eric M. Horwitz, Fox Chase Cancer Center, Philadelphia, PA; David I. Rosenthal, University of Texas MD Anderson Cancer Center, Houston, TX; Phuc Felix Nguyen-Tan, Centre Hospitalier de l'Université de Montréal-Notre Dame, Montreal; André Fortin, Hôtel-Dieu de Quebec, Quebec City, Quebec; Nancy E. Read, Western University, London Regional Cancer Center, London, Ontario, Canada; Craig L. Silverman, James Graham Brown Cancer Center, University of Louisville, Louisville, KY; Adam Raben, Christiana Care Helen F. Graham Cancer Center, Newark, DE; Harold E. Kim, Wayne State University, Detroit, MI; and Quynh-Thu Le, Stanford University, Palo Alto, CA.
Craig L SilvermanEvan J. Wuthrick and Maura L. Gillison, Ohio State University Medical Center, Columbus; Mitchell Machtay, Case Western Reserve University, Cleveland, OH; Qiang Zhang, Jonathan Harris, and Qian Wu, Radiation Therapy Oncology Group Statistical Center; Eric M. Horwitz, Fox Chase Cancer Center, Philadelphia, PA; David I. Rosenthal, University of Texas MD Anderson Cancer Center, Houston, TX; Phuc Felix Nguyen-Tan, Centre Hospitalier de l'Université de Montréal-Notre Dame, Montreal; André Fortin, Hôtel-Dieu de Quebec, Quebec City, Quebec; Nancy E. Read, Western University, London Regional Cancer Center, London, Ontario, Canada; Craig L. Silverman, James Graham Brown Cancer Center, University of Louisville, Louisville, KY; Adam Raben, Christiana Care Helen F. Graham Cancer Center, Newark, DE; Harold E. Kim, Wayne State University, Detroit, MI; and Quynh-Thu Le, Stanford University, Palo Alto, CA.
Adam RabenEvan J. Wuthrick and Maura L. Gillison, Ohio State University Medical Center, Columbus; Mitchell Machtay, Case Western Reserve University, Cleveland, OH; Qiang Zhang, Jonathan Harris, and Qian Wu, Radiation Therapy Oncology Group Statistical Center; Eric M. Horwitz, Fox Chase Cancer Center, Philadelphia, PA; David I. Rosenthal, University of Texas MD Anderson Cancer Center, Houston, TX; Phuc Felix Nguyen-Tan, Centre Hospitalier de l'Université de Montréal-Notre Dame, Montreal; André Fortin, Hôtel-Dieu de Quebec, Quebec City, Quebec; Nancy E. Read, Western University, London Regional Cancer Center, London, Ontario, Canada; Craig L. Silverman, James Graham Brown Cancer Center, University of Louisville, Louisville, KY; Adam Raben, Christiana Care Helen F. Graham Cancer Center, Newark, DE; Harold E. Kim, Wayne State University, Detroit, MI; and Quynh-Thu Le, Stanford University, Palo Alto, CA.
Harold E KimEvan J. Wuthrick and Maura L. Gillison, Ohio State University Medical Center, Columbus; Mitchell Machtay, Case Western Reserve University, Cleveland, OH; Qiang Zhang, Jonathan Harris, and Qian Wu, Radiation Therapy Oncology Group Statistical Center; Eric M. Horwitz, Fox Chase Cancer Center, Philadelphia, PA; David I. Rosenthal, University of Texas MD Anderson Cancer Center, Houston, TX; Phuc Felix Nguyen-Tan, Centre Hospitalier de l'Université de Montréal-Notre Dame, Montreal; André Fortin, Hôtel-Dieu de Quebec, Quebec City, Quebec; Nancy E. Read, Western University, London Regional Cancer Center, London, Ontario, Canada; Craig L. Silverman, James Graham Brown Cancer Center, University of Louisville, Louisville, KY; Adam Raben, Christiana Care Helen F. Graham Cancer Center, Newark, DE; Harold E. Kim, Wayne State University, Detroit, MI; and Quynh-Thu Le, Stanford University, Palo Alto, CA.
Eric M HorwitzEvan J. Wuthrick and Maura L. Gillison, Ohio State University Medical Center, Columbus; Mitchell Machtay, Case Western Reserve University, Cleveland, OH; Qiang Zhang, Jonathan Harris, and Qian Wu, Radiation Therapy Oncology Group Statistical Center; Eric M. Horwitz, Fox Chase Cancer Center, Philadelphia, PA; David I. Rosenthal, University of Texas MD Anderson Cancer Center, Houston, TX; Phuc Felix Nguyen-Tan, Centre Hospitalier de l'Université de Montréal-Notre Dame, Montreal; André Fortin, Hôtel-Dieu de Quebec, Quebec City, Quebec; Nancy E. Read, Western University, London Regional Cancer Center, London, Ontario, Canada; Craig L. Silverman, James Graham Brown Cancer Center, University of Louisville, Louisville, KY; Adam Raben, Christiana Care Helen F. Graham Cancer Center, Newark, DE; Harold E. Kim, Wayne State University, Detroit, MI; and Quynh-Thu Le, Stanford University, Palo Alto, CA.
Nancy E ReadEvan J. Wuthrick and Maura L. Gillison, Ohio State University Medical Center, Columbus; Mitchell Machtay, Case Western Reserve University, Cleveland, OH; Qiang Zhang, Jonathan Harris, and Qian Wu, Radiation Therapy Oncology Group Statistical Center; Eric M. Horwitz, Fox Chase Cancer Center, Philadelphia, PA; David I. Rosenthal, University of Texas MD Anderson Cancer Center, Houston, TX; Phuc Felix Nguyen-Tan, Centre Hospitalier de l'Université de Montréal-Notre Dame, Montreal; André Fortin, Hôtel-Dieu de Quebec, Quebec City, Quebec; Nancy E. Read, Western University, London Regional Cancer Center, London, Ontario, Canada; Craig L. Silverman, James Graham Brown Cancer Center, University of Louisville, Louisville, KY; Adam Raben, Christiana Care Helen F. Graham Cancer Center, Newark, DE; Harold E. Kim, Wayne State University, Detroit, MI; and Quynh-Thu Le, Stanford University, Palo Alto, CA.
Jonathan HarrisEvan J. Wuthrick and Maura L. Gillison, Ohio State University Medical Center, Columbus; Mitchell Machtay, Case Western Reserve University, Cleveland, OH; Qiang Zhang, Jonathan Harris, and Qian Wu, Radiation Therapy Oncology Group Statistical Center; Eric M. Horwitz, Fox Chase Cancer Center, Philadelphia, PA; David I. Rosenthal, University of Texas MD Anderson Cancer Center, Houston, TX; Phuc Felix Nguyen-Tan, Centre Hospitalier de l'Université de Montréal-Notre Dame, Montreal; André Fortin, Hôtel-Dieu de Quebec, Quebec City, Quebec; Nancy E. Read, Western University, London Regional Cancer Center, London, Ontario, Canada; Craig L. Silverman, James Graham Brown Cancer Center, University of Louisville, Louisville, KY; Adam Raben, Christiana Care Helen F. Graham Cancer Center, Newark, DE; Harold E. Kim, Wayne State University, Detroit, MI; and Quynh-Thu Le, Stanford University, Palo Alto, CA.
Qian WuEvan J. Wuthrick and Maura L. Gillison, Ohio State University Medical Center, Columbus; Mitchell Machtay, Case Western Reserve University, Cleveland, OH; Qiang Zhang, Jonathan Harris, and Qian Wu, Radiation Therapy Oncology Group Statistical Center; Eric M. Horwitz, Fox Chase Cancer Center, Philadelphia, PA; David I. Rosenthal, University of Texas MD Anderson Cancer Center, Houston, TX; Phuc Felix Nguyen-Tan, Centre Hospitalier de l'Université de Montréal-Notre Dame, Montreal; André Fortin, Hôtel-Dieu de Quebec, Quebec City, Quebec; Nancy E. Read, Western University, London Regional Cancer Center, London, Ontario, Canada; Craig L. Silverman, James Graham Brown Cancer Center, University of Louisville, Louisville, KY; Adam Raben, Christiana Care Helen F. Graham Cancer Center, Newark, DE; Harold E. Kim, Wayne State University, Detroit, MI; and Quynh-Thu Le, Stanford University, Palo Alto, CA.
Quynh-Thu LeEvan J. Wuthrick and Maura L. Gillison, Ohio State University Medical Center, Columbus; Mitchell Machtay, Case Western Reserve University, Cleveland, OH; Qiang Zhang, Jonathan Harris, and Qian Wu, Radiation Therapy Oncology Group Statistical Center; Eric M. Horwitz, Fox Chase Cancer Center, Philadelphia, PA; David I. Rosenthal, University of Texas MD Anderson Cancer Center, Houston, TX; Phuc Felix Nguyen-Tan, Centre Hospitalier de l'Université de Montréal-Notre Dame, Montreal; André Fortin, Hôtel-Dieu de Quebec, Quebec City, Quebec; Nancy E. Read, Western University, London Regional Cancer Center, London, Ontario, Canada; Craig L. Silverman, James Graham Brown Cancer Center, University of Louisville, Louisville, KY; Adam Raben, Christiana Care Helen F. Graham Cancer Center, Newark, DE; Harold E. Kim, Wayne State University, Detroit, MI; and Quynh-Thu Le, Stanford University, Palo Alto, CA.
Maura L GillisonEvan J. Wuthrick and Maura L. Gillison, Ohio State University Medical Center, Columbus; Mitchell Machtay, Case Western Reserve University, Cleveland, OH; Qiang Zhang, Jonathan Harris, and Qian Wu, Radiation Therapy Oncology Group Statistical Center; Eric M. Horwitz, Fox Chase Cancer Center, Philadelphia, PA; David I. Rosenthal, University of Texas MD Anderson Cancer Center, Houston, TX; Phuc Felix Nguyen-Tan, Centre Hospitalier de l'Université de Montréal-Notre Dame, Montreal; André Fortin, Hôtel-Dieu de Quebec, Quebec City, Quebec; Nancy E. Read, Western University, London Regional Cancer Center, London, Ontario, Canada; Craig L. Silverman, James Graham Brown Cancer Center, University of Louisville, Louisville, KY; Adam Raben, Christiana Care Helen F. Graham Cancer Center, Newark, DE; Harold E. Kim, Wayne State University, Detroit, MI; and Quynh-Thu Le, Stanford University, Palo Alto, CA.
Funding
NRG Oncology Network Group Operations Center - GY9 BIQSFP Reports/BudgetsU10CA180868 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI NORMAN WOLMARK · 2014 to 2026
$206.8MWomen's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI Keith L. Knutson · 1985 to 2026
$151.3MRTOG Foreign AccrualU10CA021661 · NCI · AMERICAN COLLEGE OF RADIOLOGY · PI CURRAN, WALTER J. · 1985 to 2013
$150.3MStatistics CoreU10CA180822 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI James J. Dignam, GREG YOTHERS · 2014 to 2026
$146.4MNCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer CareUG1CA233180 · NCI · DANA-FARBER CANCER INST · PI Harold John Burstein · 2019 to 2026
$8.6MOSU as Network Lead Academic Participating Site for the NCI NCTNU10CA180850 · NCI · OHIO STATE UNIVERSITY · PI BLUM, KRISTIE A, CHAKRAVARTI, ARNAB · 2014 to 2018
$6.8MNCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer CareU10CA180867 · NCI · DANA-FARBER CANCER INST · PI BURSTEIN, HAROLD JOHN, KIBEL, ADAM S · 2014 to 2018
$6.2MNCI NIH HHS P30 CA015083NCI NIH HHS U10 CA021661NCI NIH HHS U10 CA180822NCI NIH HHS U10 CA180850NCI NIH HHS U10 CA180867NCI NIH HHS U10 CA180868NCI NIH HHS UG1 CA233180
Abstract
purposeNational Comprehensive Cancer Network guidelines recommend patients with head and neck cancer (HNC) receive treatment at centers with expertise, but whether provider experience affects survival is unknown. PATIENTS AND
methodsThe effect of institutional experience on overall survival (OS) in patients with stage III or IV HNC was investigated within a randomized trial of the Radiation Therapy Oncology Group (RTOG 0129), which compared cisplatin concurrent with standard versus accelerated fractionation radiotherapy. As a surrogate for experience, institutions were classified as historically low- (HLACs) or high-accruing centers (HHACs) based on accrual to 21 RTOG HNC trials (1997 to 2002). The effect of accrual volume on OS was estimated by Cox proportional hazards models.
resultsMedian RTOG accrual (1997 to 2002) at HLACs was four versus 65 patients at HHACs. Analysis included 471 patients in RTOG 0129 (2002 to 2005) with known human papillomavirus and smoking status. Patients at HLACs versus HHACs had better performance status (0: 62% v 52%; P = .04) and lower T stage (T4: 26.5% v 35.3%; P = .002) but were otherwise similar. Radiotherapy protocol deviations were higher at HLACs versus HHACs (18% v 6%; P < .001). When compared with HHACs, patients at HLACs had worse OS (5 years: 51.0% v 69.1%; P = .002). Treatment at HLACs was associated with increased death risk of 91% (hazard ratio [HR], 1.91; 95% CI, 1.37 to 2.65) after adjustment for prognostic factors and 72% (HR, 1.72; 95% CI, 1.23 to 2.40) after radiotherapy compliance adjustment.
conclusionOS is worse for patients with HNC treated at HLACs versus HHACs to cooperative group trials after accounting for radiotherapy protocol deviations. Institutional experience substantially influences survival in locally advanced HNC.
Indexed as
ChemoradiotherapyDose Fractionation, RadiationPatient SelectionAdultAgedAntineoplastic AgentsCarcinoma, Squamous CellCisplatinDisease-Free SurvivalFemaleHead and Neck NeoplasmsHumansKaplan-Meier EstimateMaleMiddle AgedNeoplasm StagingAntineoplastic AgentsCisplatin
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.